| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000014445 |
| Receipt No. | R000016806 |
| Official scientific title of the study | Clinical efficacy of Eribulin new for metastatic breast cancer |
| Date of disclosure of the study information | 2014/07/01 |
| Last modified on | 2018/04/01 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Clinical efficacy of Eribulin new for metastatic breast cancer | |
| Title of the study (Brief title) | Clinical efficacy of Eribulin new for metastatic breast cancer | |
| Region |
|
|
| Condition | ||||
| Condition | progressive or metastatic breast cancer patients | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Malignancy | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | Efficacy of using Eribrin |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | OS,PFS |
| Key secondary outcomes | ORR,TTF,adverse ebents |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | For breast cancer metastasis cases, cases it was invalid be administered an anti-cancer agent anthracycline, taxane-based in the designated facilities. | |||
| Key exclusion criteria | Patients who sustain adverse events using after taxanes.
Patients who have not enough judgment ability minors, in adults, cases of acquisition agreement by the description document is difficult. Patients who are subjected to treatment without their doctors not revealing the breast cancer treatment. |
|||
| Target sample size | 120 | |||
| Research contact person | |
| Name of lead principal investigator | Tada Keiichirou |
| Organization | Graduate School of Medicine and Faculty of Medicine, the University of Tokyo |
| Division name | Breast and Endocrine Surgery Department |
| Address | Hongo, 7-3-1, Bunkyo-ku, Tokyo, Japan |
| TEL | 03-5800-9538 |
| TADAK-SUR@h.u-tokyo.ac.jp | |
| Public contact | |
| Name of contact person | Kikuchi Yasuko |
| Organization | Graduate School of Medicine and Faculty of Medicine, the University of Tokyo |
| Division name | Breast and Endocrine Surgery Department |
| Address | Hongo, 7-3-1, Bunkyo-ku, Tokyo, Japan |
| TEL | 03-5800-9538 |
| Homepage URL | |
| kikuchiy-sur@h.u-tokyo.ac.jp | |
| Sponsor | |
| Institute | Graduate School of Medicine and Faculty of Medicine, the University of Tokyo |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Graduate School of Medicine and Faculty of Medicine, the University of Tokyo |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 国際医療福祉大学三田病院(東京都)、公立昭和病院(東京都)、国立国際医療センター(東京都)、虎ノ門病院(東京都)、関東中央病院(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | https://onlinelibrary.wiley.com/doi/full/10.1111/ajco.12863 |
| Results | |
| Other related information | Analysis about background of the patient being administered,occurrence of adverse events, presence or absence of pre-treatment, administration period, during treatment, the treatment duration of response, analysis of tumor reduction rate of the image evaluation |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000016806 |